NTRK Fusion Gene Positive Advanced Solid Tumor Market Trends

Growth Drivers

• Growing Trend for Personalized Treatment - By raising the need for genetic testing, the emergence of personalized treatment strategies is also fueling the market expansion for advanced solid tumors that are positive for the NTRK fusion gene. As per a report, by 2022, medicines, diagnostics, and personalized medical care should account for almost 40% of the total. The precise genetic alterations that lead to the formation of NTRK fusion gene-positive advanced solid tumors are found through genetic testing. The NTRK fusion gene positive advanced solid tumor market is expanding due to the growing need for precision medicine specialists such as genetic counsellors and other healthcare experts, who are in high demand due to the emergence of individualized treatment regimens.
• Increased Prevalence of Solid Cancer Types - Since NTRK fusions are present in the majority of solid cancer types, their prevalence rate is higher. This is anticipated to propel the market for advanced solid tumors with NTRK fusion genes. The discovery of novel medications is anticipated to propel the market for NTRK fusion gene-positive advanced solid tumors. NTRK is a distinct gene that has significance in numerous types of cancers. Also, the development of targeted therapies specifically designed to inhibit NTRK fusion proteins has led to improved outcomes for patients with NTRK fusion-positive tumors. For instance, the FDA approved entrectinib (Rozlytrek) on October 20, 2023, for the treatment of solid tumors in children as young as one month old. For those 12 years of age or older, the FDA approved the medication in 2019.
• Growing Technological Advancements in Genetic Testing – Advanced genetic testing methods, such as next-generation sequencing (NGS), are more sensitive and accurate in detecting genetic alterations like NTRK fusions. Also, improved genetic testing allows for earlier detection of NTRK fusion-positive tumors, enabling patients to receive targeted therapies at earlier stages of the disease. For instance, in 2022, the next-generation sequencing (NGS) platform, the CE-IVD designated Ion Torrent Genexus Dx Integrated Sequencer, was introduced by Thermo Fisher Scientific as an automated system that produces data in a single day. With the platform, users may do clinical research and diagnostic testing on a single device-it is intended for use in clinical laboratories. Moreover, genetic testing panels that include a wide range of genetic alterations, including NTRK fusions, are becoming more common in clinical practice.

Challenges

• High Costs Related to the Targeted Therapies – Targeted therapies can be expensive, posing challenges for patient access, especially in regions with limited healthcare resources or inadequate insurance coverage. Therefore, inadequate healthcare infrastructure and exorbitant expenses linked to NTRK fusion gene screening could potentially impede the future expansion of the NTRK fusion gene-positive advanced solid tumor market.
• Complexity in Identifying the Patients may hinder the Market Growth.
• Lack of Skilled Laboratory Technicians May Hamper the Market Growth